Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
NCT07314060

A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis

Led by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Updated on 2026-03-24

36

Participants Needed

32

Research Sites

67 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study, all subjects need to use TQH2929 injection/placebo. The aim was to demonstrate the efficacy and safety of TQH2929 injection in patients with acute exacerbations of generalized pustular psoriasis, with a total of 36 subjects.

CONDITIONS

Official Title

A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 to 75 years at screening, any gender
  • Diagnosed with generalized pustular psoriasis according to 2017 ERASPEN criteria
  • Experiencing an acute flare-up of generalized pustular psoriasis
  • Able to read, understand, and willing to sign informed consent
  • Willing and able to comply with study visits and procedures
  • Female participants of childbearing potential agree to use contraception during the study and for 6 months after
Not Eligible

You will not qualify if you...

  • Pustules limited only to psoriasis plaques (psoriasis vulgaris)
  • Skin or medical conditions that interfere with treatment response evaluation
  • Severe, progressive, or uncontrolled disease deemed unsuitable by investigator
  • Abnormal serum virology during screening
  • Active tuberculosis, recent contact with tuberculosis, or positive IGRA test
  • Serious infection requiring hospitalization within 2 months before baseline
  • Active infection needing systemic antibiotic, antifungal, or antiviral treatment within 2 weeks before baseline
  • Opportunistic infection within 6 months prior to baseline
  • Live (attenuated) vaccine within 12 weeks prior to baseline
  • Major surgery within 4 weeks prior to baseline or planned during study
  • Blood transfusion within 4 weeks prior to baseline
  • Participation in other drug or device trials within 4 weeks before baseline
  • Known or suspected immunodeficiency compromising immune status
  • Active malignancy or history of malignancy
  • Alcohol, drug, or known drug dependence
  • Pregnant or breastfeeding women
  • Unable to tolerate intravenous infusion administration

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 32 locations

1

Peking University First Hospita

Beijing, Beijing Municipality, China, 100034

Actively Recruiting

2

Peking University Third Hospital

Beijing, Beijing Municipality, China, 100191

Not Yet Recruiting

3

The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, China, 350000

Not Yet Recruiting

4

Southern Medical University Dermatology Hospital

Guangzhou, Guangdong, China, 510091

Not Yet Recruiting

5

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Guangzhou, Guangdong, China, 510120

Not Yet Recruiting

6

The Affiliated Hospital of Guizhou Medical University

Guiyang, Guizhou, China, 550004

Not Yet Recruiting

7

The Second Hospital Of Hebei Medical University

Shijiazhuang, Hebei, China, 050000

Not Yet Recruiting

8

The Second Affiliated Hospital of Henan University of science and technology

Luoyang, Henan, China, 471000

Not Yet Recruiting

9

Zhengzhou Central Hospital

Zhengzhou, Henan, China, 450000

Not Yet Recruiting

10

Henan Provincial People's Hospital

Zhengzhou, Henan, China, 450003

Not Yet Recruiting

11

The fifth Affiliated hospital of zhengzhou university

Zhengzhou, Henan, China, 450052

Not Yet Recruiting

12

Shiyan Renmin Hospital

Shiyan, Hubei, China, 442000

Not Yet Recruiting

13

Renmin Hospital of Wuhan University

Wuhan, Hubei, China, 430060

Not Yet Recruiting

14

The First Hospital of Hunan University of Chinese Medicine

Changsha, Hunan, China, 410007

Not Yet Recruiting

15

Xiangya Hospital of Central South University

Changsha, Hunan, China, 410008

Not Yet Recruiting

16

The General Hospital Of Hunan University Of Medicine

Huaihua, Hunan, China, 41800

Not Yet Recruiting

17

The first hospital of jilin university

Changchun, Jilin, China, 130012

Not Yet Recruiting

18

The first hospital of china medical university

Shenyang, Liaoning, China, 110001

Not Yet Recruiting

19

Shandong First Medical University Affiliated Dermatology Hospital

Jinan, Shandong, China, 250022

Not Yet Recruiting

20

Shanghai Skin Disease Hospital

Shanghai, Shanghai Municipality, China, 200443

Not Yet Recruiting

21

The Second Affiliated Hospital of Xi'an Jiaotong University

Xi’an, Shanxi, China, 710061

Not Yet Recruiting

22

Chengdu Second People's Hospital

Chengdu, Sichuan, China, 610000

Not Yet Recruiting

23

Sichuan Provincial People' s Hospital

Chengdu, Sichuan, China, 610000

Not Yet Recruiting

24

The Affiliated Hospital of Southwest Medical University

Luzhou, Sichuan, China, 646000

Not Yet Recruiting

25

The Affiliated Hospital of Southwest Medical University

Luzhou, Sichuan, China, 646000

Not Yet Recruiting

26

Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, China, 300052

Not Yet Recruiting

27

Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital

Tianjin, Tianjin Municipality, China, 300120

Not Yet Recruiting

28

People's Hospital of Xinjiang Uygur Autonomous Region

Ürümqi, Xinjiang, China, 830001

Not Yet Recruiting

29

The First Affiliated Hospital of Xinjiang Medical University

Ürümqi, Xinjiang, China, 830013

Not Yet Recruiting

30

The First Affiliated Hospital of Kunming Medical University

Kunming, Yunnan, China, 650032

Not Yet Recruiting

31

Jiaxing First Hospital

Jiaxing, Zhejiang, China, 314001

Not Yet Recruiting

32

The first affiliated hospital of ningbo university

Ningbo, Zhejiang, China, 315020

Not Yet Recruiting

Loading map...

Research Team

H

Hang Li, Doctor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here